The Real World AI Stage at TechCrunch Disrupt 2026 will host a fireside chat titled “Can We Engineer Nature’s Comeback?” with Ben Lamm, co‑founder and CEO of Colossal Biosciences, where he will explain how the company combines artificial intelligence and synthetic biology to pursue de‑extinction.
Event specifics
TechCrunch Disrupt runs from 13 October to 15 October 2026 at the Moscone Center in San Francisco. The Real World AI Stage is one of six industry‑focused stages at the conference. The fireside chat is scheduled as part of that stage, according to TechCrunch’s announcement on 14 September 2026.
Colossal Biosciences at a glance
| Item | Value |
|---|---|
| Name | Colossal Biosciences |
| Headquarters | Dallas, United States |
| Founded | 13 September 2021 |
| Industry | Biotechnology |
| Employees | 85 (as listed in Wikidata; the entry notes the figure may be outdated) |
The company describes itself as a “billion‑dollar startup” focused on bringing extinct species back to life. Ben Lamm is identified by TechCrunch as both co‑founder and chief executive.
AI meets synthetic biology
TechCrunch’s coverage notes that the session will explore “where AI and synthetic biology intersect.” Researchers, according to the same source, are using AI to analyze genetic data, model biological systems, and accelerate discovery. The article frames these advances as moving questions that “until recently belonged in science‑fiction” into the realm of practical research.
By positioning AI as a tool that moves beyond purely digital applications and into the natural world, Colossal is part of a broader trend where computational methods accelerate wet‑lab work. The excerpt emphasizes that “advances in artificial intelligence, genetics, and computational biology are changing what’s possible in conservation research,” suggesting a shift in how biotech firms approach large‑scale biological challenges.
Sector outlook and investor implications
The convergence of AI and biotech has attracted both capital and ethical scrutiny. While the packet does not provide valuation multiples or revenue figures, the description of Colossal as a “billion‑dollar startup” signals that investors are already allocating significant funds to AI‑enabled de‑extinction projects.
For venture capitalists tracking frontier technologies, the fireside chat offers a concrete example of how AI can be leveraged to reduce the time and cost of genome reconstruction. If the techniques discussed prove scalable, they could lower barriers for other synthetic‑biology ventures, potentially expanding the addressable market for AI‑driven biotech platforms.
Conversely, the same excerpt raises broader questions about the role of AI in biodiversity. The phrase “should it?” hints at a debate that may affect regulatory attitudes and public perception, factors that can influence funding rounds and partnership opportunities.
What remains unknown
- The packet does not disclose the specific species that Colossal intends to target first, nor the projected timeline for any successful de‑extinction.
- Employee headcount and leadership details come from Wikidata, which the packet flags as potentially lagging behind current reality.
- Financial metrics such as revenue, cash burn, or fundraising rounds are absent, limiting a precise assessment of the company’s financial health.
TechCrunch’s announcement does not specify the format of the discussion beyond the title, so the depth of technical detail that will be shared remains uncertain.
Looking ahead
TechCrunch Disrupt 2026 will be the first public forum where Colossal Biosciences lays out its AI‑driven de‑extinction roadmap. Investors and industry observers will watch for signals about the scalability of AI tools in synthetic biology, potential regulatory hurdles, and the broader market appetite for projects that sit at the intersection of conservation and cutting‑edge computation.
Whether the conversation translates into new partnerships, funding commitments, or policy discussions will become clearer in the weeks following the event.